Évaluation de l’imatinib dans la prise en charge de la leucémie myéloïde chronique au Gabon À propos de dix-sept cas Volume 26, numéro 2, Avril-Mai- Juin. REVUE MEDICALE DE LIEGE. Cliquer ICI pour déclencher le téléchargement de l’article. COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE. Résumé La leucémie myéloïde chronique (LMC) est un modèle de cancérogenèse. Son pronostic a été exceptionnellement amélioré grâce.
|Published (Last):||2 June 2007|
|PDF File Size:||19.30 Mb|
|ePub File Size:||3.58 Mb|
|Price:||Free* [*Free Regsitration Required]|
A retrospective study of leukemia epidemiology in Northern Tunisia.
RMLG – ACCES A L’ARTICLE :COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE (LMC).
You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted. Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi. Imatinib chronnique therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.
New strategies to eradicate these residual cells by targeting the hematopoietic niche leucejie directly the leukemic stem cells are being developed. S Af Med J.
Biologie moléculaire de la leucémie myéloïde chronique : dernières avancées – EM|consulte
Access to the full text of this article requires a subscription. Chronic myeloid leukaemia in central Africans. New technologies digital PCR, high-throughput sequencing or NGS were developed to improve the performances of existing methods. Personal information regarding our website’s visitors, including their identity, is confidential.
Journal page Archives Contents list. Hematologic and chroniquee response to Imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. Access to the text HTML.
Chronic myeloid leukaemia in South African blacks. As per the Law relating to information storage and personal integrity, myeloire have the right to oppose art 26 of that lawaccess art 34 of that law and rectify art 36 of that law your personal data. Les inhibiteurs des kinases. The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Molecular biology of bcr-abl1-positive CML.
Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction.
Contact Help Who are we? If you are a subscriber, please sign in ‘My Myelide at the top right of the screen. Access to the PDF text. Chronic myeloid leukemia advances in biology and new approaches to treatment.
Tyrosine kinase inhibitor TKI therapy imatinib, dasatinib, nilotinib, bosutinib, myelpide has led to improved overall and disease-free survival of patients. Finally, the immune system undoubtedly plays a crucial function in the control of residual leukemic cells; this role should be specified in the future.
An experience from eastern India. You can move this window by clicking on the headline.
Leucémie myéloïde chronique (LMC)
For the remaining half of patients, the causes leading to the molecular relapse deserve to be further analyzed. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries.
East Afr Med J. Indian J Hematol Blood Transfus.
Clinical trials have validated TKI discontinuation strategies in patients with sustained deep molecular response. Outline Masquer le plan.
If you want to subscribe to this journal, see our rates You can chroonique this item in Pay Per View: Top of the page – Article Outline. Clinical and pronognostic features of Nigerians with chronic myeloid leukemia.
International recommendations facilitate the management of CML and treatment adjustments. The Glivec international patient assistance programme: